318 related articles for article (PubMed ID: 32242050)
1. Treatment and unmet needs in steroid-refractory acute graft-versus-host disease.
Malard F; Huang XJ; Sim JPY
Leukemia; 2020 May; 34(5):1229-1240. PubMed ID: 32242050
[TBL] [Abstract][Full Text] [Related]
2. Mesenchymal stromal cell therapy for steroid-refractory acute and chronic graft versus host disease: a phase 1 study.
Herrmann R; Sturm M; Shaw K; Purtill D; Cooney J; Wright M; Phillips M; Cannell P
Int J Hematol; 2012 Feb; 95(2):182-8. PubMed ID: 22183779
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of mesenchymal stromal cell therapy for multi-drug-resistant acute and late-acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation.
Keklik M; Deveci B; Celik S; Deniz K; Gonen ZB; Zararsiz G; Saba R; Akyol G; Ozkul Y; Kaynar L; Keklik E; Unal A; Cetin M; Jones OY
Ann Hematol; 2023 Jun; 102(6):1537-1547. PubMed ID: 37067556
[TBL] [Abstract][Full Text] [Related]
4. C-Reactive Protein Levels at Diagnosis of Acute Graft-versus-Host Disease Predict Steroid-Refractory Disease, Treatment-Related Mortality, and Overall Survival after Allogeneic Hematopoietic Stem Cell Transplantation.
Minculescu L; Kornblit BT; Friis LS; Schiødt I; Petersen SL; Andersen NS; Sengeloev H
Biol Blood Marrow Transplant; 2018 Mar; 24(3):600-607. PubMed ID: 29074374
[TBL] [Abstract][Full Text] [Related]
5. Long-Term Follow-Up After the Application of Mesenchymal Stromal Cells in Children and Adolescents with Steroid-Refractory Graft-Versus-Host Disease.
Döring M; Cabanillas Stanchi KM; Lenglinger K; Treuner C; Gieseke F; Erbacher A; Mezger M; Vaegler M; Schlegel PG; Greil J; Bettoni da Cunha Riehm C; Faul C; Schumm M; Lang P; Handgretinger R; Müller I
Stem Cells Dev; 2021 Mar; 30(5):234-246. PubMed ID: 33446053
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of Mesenchymal Stem Cell Therapy for Steroid-Refractory Acute Graft-Versus-Host Disease following Allogeneic Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis.
Chen X; Wang C; Yin J; Xu J; Wei J; Zhang Y
PLoS One; 2015; 10(8):e0136991. PubMed ID: 26323092
[TBL] [Abstract][Full Text] [Related]
7. Extended Treatment With Mesenchymal Stromal Cells-Frankfurt am Main in a Pediatric Patient With Steroid-refractory Acute Gastrointestinal Graft-Versus-Host Disease: Case Report and Review of the Literature.
Gruhn B; Brodt G; Ernst J
J Pediatr Hematol Oncol; 2021 Apr; 43(3):e419-e425. PubMed ID: 32118816
[TBL] [Abstract][Full Text] [Related]
8. Allogeneic human mesenchymal stem cell therapy (remestemcel-L, Prochymal) as a rescue agent for severe refractory acute graft-versus-host disease in pediatric patients.
Kurtzberg J; Prockop S; Teira P; Bittencourt H; Lewis V; Chan KW; Horn B; Yu L; Talano JA; Nemecek E; Mills CR; Chaudhury S
Biol Blood Marrow Transplant; 2014 Feb; 20(2):229-35. PubMed ID: 24216185
[TBL] [Abstract][Full Text] [Related]
9. The efficiency of human umbilical cord mesenchymal stem cells as a salvage treatment for steroid-refractory acute graft-versus-host disease.
Ding Y; Liu C; Cai Y; Hou C; Chen G; Xu Y; Hu S; Wu D
Clin Exp Med; 2023 Oct; 23(6):2561-2570. PubMed ID: 36598673
[TBL] [Abstract][Full Text] [Related]
10. Tocilizumab as first-line therapy for steroid-refractory acute graft-versus-host-disease: analysis of a single-center experience.
Yucebay F; Matthews C; Puto M; Li J; William B; Jaglowski SM; Penza SL; Vasu S; Benson DM; Andritsos LA; Devine SM; Efebera YA; Roddy JVF
Leuk Lymphoma; 2019 Sep; 60(9):2223-2229. PubMed ID: 30764681
[TBL] [Abstract][Full Text] [Related]
11. Successful treatment with placenta-derived decidual stromal cells in a pediatric patient with life-threatening acute gastrointestinal graft-versus-host disease.
Gustafsson B; Frisk P; Szakos A; Sadeghi B; Ringdén O; Frost BM
Pediatr Transplant; 2017 Aug; 21(5):. PubMed ID: 28612364
[TBL] [Abstract][Full Text] [Related]
12. Gastrointestinal acute graft-versus-host disease in children: histology for diagnosis, mesenchymal stromal cells for treatment, and biomarkers for prediction of response.
Calkoen FG; Jol-van der Zijde CM; Mearin ML; Schweizer JJ; Jansen-Hoogendijk AM; Roelofs H; van Halteren AG; Egeler RM; van Tol MJ; Ball LM
Biol Blood Marrow Transplant; 2013 Nov; 19(11):1590-9. PubMed ID: 23994245
[TBL] [Abstract][Full Text] [Related]
13. Children and Adults with Refractory Acute Graft-versus-Host Disease Respond to Treatment with the Mesenchymal Stromal Cell Preparation "MSC-FFM"-Outcome Report of 92 Patients.
Bonig H; Kuçi Z; Kuçi S; Bakhtiar S; Basu O; Bug G; Dennis M; Greil J; Barta A; Kállay KM; Lang P; Lucchini G; Pol R; Schulz A; Sykora KW; Teichert von Luettichau I; Herter-Sprie G; Ashab Uddin M; Jenkin P; Alsultan A; Buechner J; Stein J; Kelemen A; Jarisch A; Soerensen J; Salzmann-Manrique E; Hutter M; Schäfer R; Seifried E; Paneesha S; Novitzky-Basso I; Gefen A; Nevo N; Beutel G; Schlegel PG; Klingebiel T; Bader P
Cells; 2019 Dec; 8(12):. PubMed ID: 31817480
[TBL] [Abstract][Full Text] [Related]
14. Mesenchymal stromal cells for steroid-refractory acute graft-versus-host disease: a report of two cases.
Lim JH; Lee MH; Yi HG; Kim CS; Kim JH; Song SU
Int J Hematol; 2010 Jul; 92(1):204-7. PubMed ID: 20514533
[TBL] [Abstract][Full Text] [Related]
15. Immunomodulation effects of mesenchymal stromal cells on acute graft-versus-host disease after hematopoietic stem cell transplantation.
Zhao K; Lou R; Huang F; Peng Y; Jiang Z; Huang K; Wu X; Zhang Y; Fan Z; Zhou H; Liu C; Xiao Y; Sun J; Li Y; Xiang P; Liu Q
Biol Blood Marrow Transplant; 2015 Jan; 21(1):97-104. PubMed ID: 25300866
[TBL] [Abstract][Full Text] [Related]
16. Bowel wall thickness is a strong predictor of steroid-refractory acute graft-versus-host disease with gut involvement after allo-HSCT.
Drokov M; Yatsyk G; Kireeva A; Pirikova O; Dubnyak D; Kuzmina L; Vasilyeva V; Popova N; Starikova O; Parovichnikova E; Savchenko V
Int J Hematol; 2022 Apr; 115(4):545-552. PubMed ID: 35098481
[TBL] [Abstract][Full Text] [Related]
17. Novel therapies for graft versus host disease with a focus on cell therapies.
Zeiser R; Ringden O; Sadeghi B; Gonen-Yaacovi G; Segurado OG
Front Immunol; 2023; 14():1241068. PubMed ID: 37868964
[TBL] [Abstract][Full Text] [Related]
18. Pathophysiology of gastrointestinal acute graft-versus-host disease and the potential role of glucagon-like peptide 2.
Zeiser R; Chen YB; Youssef NN; Ayuk F
Br J Haematol; 2023 May; 201(4):620-627. PubMed ID: 36965050
[TBL] [Abstract][Full Text] [Related]
19. How I treat steroid-refractory acute graft-versus-host disease.
Martin PJ
Blood; 2020 May; 135(19):1630-1638. PubMed ID: 32202630
[TBL] [Abstract][Full Text] [Related]
20. Recombinant human soluble tumor necrosis factor receptor fusion protein as treatment for steroid refractory graft-versus-host disease following allogeneic hematopoietic stem cell transplantation.
Busca A; Locatelli F; Marmont F; Ceretto C; Falda M
Am J Hematol; 2007 Jan; 82(1):45-52. PubMed ID: 16937391
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
